Table 1.
Demographics on all patients enrolled on study (n = 45): total and by cohort. Q2 cohort, patients treated with temsirolimus and capecitabine on a 2‐week schedule; Q3 cohort, patients treated with temsirolimus and capecitabine on a 3‐week schedule; expansion cohort, patients treated with temsirolimus and capecitabine plus oxaliplatin on a 2‐week schedule
|
All N (%) |
Q2 Cohort N (%) |
Q3 Cohort N (%) |
Expansion Cohort N (%) |
||
|---|---|---|---|---|---|
| All patients | 45 (100%) | 23 (51%) | 15 (33%) | 7 (16%) | |
| Category | Group | ||||
| Age ‐ median | 60 | 67 | 58 | 56 | |
| Gender | Male | 28 (62%) | 14 (61%) | 8 (53%) | 6 (86%) |
| Female | 17 (38%) | 9 (39%) | 7 (47%) | 1 (14%) | |
| Race | White | 33 (73%) | 18 (78%) | 11 (73%) | 4 (57%) |
| Black | 9 (20%) | 3 (13%) | 3 (20%) | 3 (43%) | |
| Asian | 2 (4%) | 2 (9%) | |||
| Missing | 1 (2%) | 1 (7 %) | |||
| Primary tumor site | Colorectal | 24 (53%) | 14 (61%) | 7 (47%) | 3 (33%) |
| Pancreas | 9 (20%) | 5 (22%) | 3 (20%) | 1 (14%) | |
| Lung | 3 (7%) | 2 (9%) | 1 (7%) | ||
| Appendix | 2 (4%) | 2 (13%) | |||
| Bile Duct | 1 (2%) | 1 (14%) | |||
| Breast | 1 (2%) | 1 (14%) | |||
| Esophagus | 1 (2%) | 1 (7%) | |||
| Jejunum | 1 (2%) | 1 (14%) | |||
| Kidney | 1 (2%) | 1 (7%) | |||
| Other | 1 (2%) | 1 (4%) | |||
| Vagina | 1 (2%) | 1 (4%) | |||
| ECOG | 0 | 15 (33%) | 8 (35%) | 5 (33%) | 2 (29%) |
| 1 | 29 (64%) | 15 (65%) | 9 (60%) | 5 (71%) | |
| 2 | 1 (2%) | 1 (7%) |